Oral ddAVP for nighttime urinary incontinence in characterized nursing home residents: a pilot study

What Was Tested

This controlled clinical trial paper looks at Vasopressin and Desmopressin.

To (1) identify abnormalities in arginine vasopressin (AVP, a water-conserving hormone) secretion and release in nursing home (NH) residents with nighttime urinary incontinence (UI); and (2) perform a pilot test of desmopressin acetate (ddAVP, a synthetic analog of the naturally occurring hormone) replacement in these residents.

Who Took Part

By PubMed's age tags, the people studied were older adults and people over 80, both men and women.

Diagnostic evaluation and open-label treatment trial.

How the Study Was Run

The design is described as open-label and pilot.

Everyone knew when Vasopressin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It is described as a pilot, a small early test of whether a larger Vasopressin study would be practical.

Two community nursing homes in a metropolitan area.

Male and female NH residents 65 years of age and older with nighttime UI.

Water deprivation test results, AVP levels, voided volumes, number of voids, incontinent episodes, number of nighttime checks found wet (out of 6 total checks per night).

What Was Measured

Topics PubMed links to this paper include Age Factors, Antidiuretic Agents, Arginine Vasopressin, Deamino Arginine Vasopressin, Diapers, Adult, Enuresis and Geriatric Assessment.

What This Means in Plain Language

The paper is an open-label and pilot study of Vasopressin and Desmopressin.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Journal of the American Medical Directors Association), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.